Aradigm Corp. (ARDM.OB) Releases Positive Phase 2b Data for Lung Disease Treatment
Specialty pharmaceutical company Aradigm Corp. is focused on the development of its portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. Its portfolio includes product candidates to treat bronchiectasis, cystic fibrosis, inhalation anthrax and tularemia infections and smoking cessation. The company today announced that statistical significance was achieved in the company’s recently concluded six-month phase 2b study (ORBIT-2) with Aradigm's once-daily dual release ciprofloxacin for inhalation (DRCFI, ARD-3150) in patients with non-cystic fibrosis bronchiectasis, a lung disease in which airways enlarge. Associate Professor David Serisier of the Mater Adult Hospital, Brisbane, Australia, a pulmonary physician and…